The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young children--Rare pediatric disease designation provides for a Priority Review Voucher (PRV) subject to certain conditions --This new designation is in addition to opaganib's current neuroblastoma orphan drug designation, providing for potential benefits such as accelerated development and review times, FDA Prescription Drug User Fee Act (PDUFA) application fee waivers, tax credits and seven-years' marketing exclusivity, if approved--New preclinical data, presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, ...

XIAMEN, China, June 10, 2026 /PRNewswire/ -- POP Culture Group Co., Ltd. (Nasdaq: CPOP, "POP Culture" or the "Company"), today announced its unaudited financial results for six months ended December 31, 2025. During the reporting period, the Company achieved significant growth in its core business, with strong revenue expansion, improved gross profit, and continued optimization of its cost structure. Overall, the Company demonstrated a sound and favorable trajectory of high-speed growth, reflecting strong operational resilience and substantial growth potential.

SHANGHAI, June 8, 2026 /PRNewswire/ -- Gamehaus Holdings Inc. ("Gamehaus" or the "Company") (Nasdaq: GMHS), a technology-driven mobile game publisher, today announced its unaudited financial results for the third quarter of fiscal year 2026 ended March 31, 2026.

HONG KONG, June 9, 2026 /PRNewswire/ -- Euro Tech Holdings Company Limited (Nasdaq: CLWT) today announces the launch of its next-generation mobile hybrid facility designed specifically for the treatment of ballast water aboard maritime vessels. This cutting-edge product aims to facilitate compliance with the International Maritime Organization's D2 regulations and growing local environmental protection standards, particularly in Europe, where regulations are becoming increasingly stringent.